Leukemia and Lymphoma
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.
2022
-
Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013
2003
-
The development of a practice guideline for treating newly diagnosed patients with chronic myelocytic leukemia
1998
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure..
ahead-of-print:1-10.
2025
-
Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice..
66:190-203.
2025
-
Improvement in quality of life in MDS patients who become transfusion independent after treatment..
66:279-288.
2025
-
Are we maintaining minimal residual disease in myeloma?.
ahead-of-print:1-9.
2025
-
Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement..
66:16-25.
2025
-
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.
65:1-8.
2024
-
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
65:1-14.
2024
-
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).
65:1167-1174.
2024
-
The successful management of acute promyelocytic leukemia during pregnancy: a case report.
65:526-529.
2024
-
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
64:651-661.
2023
-
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.
63:3208-3216.
2022
-
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
62:1525-1527.
2021
-
Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib.
62:495-497.
2021
-
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
61:3287-3305.
2020
-
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma.
61:1097-1107.
2020
-
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
60:3493-3502.
2019
-
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.
60:1399-1408.
2019
-
Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.
60:133-141.
2019
-
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
58:2319-2327.
2017
-
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013.
58:1805-1813.
2017
-
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
58:1358-1365.
2017
-
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*.
58:64-69.
2017
-
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
57:1463-1466.
2016
-
Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
57:1300-1310.
2016
-
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
56:2793-2802.
2015
-
Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials.
54:1479-1487.
2013
-
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
54:760-766.
2013
-
Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis.
53:878-885.
2012
-
Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
53:57-63.
2012
-
Corrigendum.
52:1160-1160.
2011
-
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
52:394-399.
2011
-
Pentostatin-induced hypereosinophilia with eosinophilic gastroenteritis.
51:1567-1569.
2010
-
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
51:252-260.
2010
-
Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria.
48:513-520.
2007
-
Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K, et al. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006;47:967 – 977.
47:1719-1720.
2006
-
Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate.
47:297-306.
2006
-
Yttrium 90 ibritumomab tiuxetan in lymphoma.
47:967-977.
2006
-
A marine fish diet reduces spontaneous lymphoma in outbred Swiss-Webster mice.
46:1797-1800.
2005
-
An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma.
45:2471-2476.
2004
-
CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature.
44:955-962.
2003
-
Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma.
44:29-37.
2003
-
Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study.
43:1581-1587.
2002
-
A Comparison of Elderly Patients with Aggressive Histology Lymphoma who Were Entered or Not Entered on to a Randomized Phase II Trial.
38:327-334.
2000
-
A Prospective Randomized Study of Alpha-2b Interferon plus Hydroxyurea or Cytarabine for Patients with Early Chronic Phase Chronic Myelogenous Leukemia: The International Oncology Study Group CML1 Study.
37:367-377.
2000
-
A Phase I Trial of Standard and Cyclophosphamide Dose-Escalated CHOP with Granulocyte Colony Stimulating Factor in Elderly Patients with Non-Hodgkin's Lymphoma.
30:591-600.
1998
-
The Development of a Practice Guideline for Treating Newly Diagnosed Patients with Chronic Myelocytic Leukemia.
30:24-26.
1998
-
Telomeres and Telomerase in Normal and Malignant Haematologic Cells.
24:1-9.
1996
-
Dysregulation of HOX11 by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer.
16:209-215.
1995
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)